Data for a five-year study and an ongoing trial revealed that long-term treatment with Zeposia (ozanimod) may stabilize or improve cognitive function among relapsing-remitting MS patients.
These findings were more pronounced among patients with greater brain volumes.
This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service, or treatment.